Pricing Log in Create free account
Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

KYMR Healthcare Biotechnology

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue
+466.4%
EPS
−40.3%
Free cash flow
−186.6%
Total debt
−66.6%

Quarter to September 2026, against a year earlier

132.01 3.89 +3.04%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
4/9
Altman Z
23.22
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Kymera Therapeutics, Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 7:15 AM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 5, 2026: no comparison — low extraction confidence